Symmune Therapeutics Overview

  • Founded
  • 2015
  • Status
  • Private
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $125K
Latest Deal Amount

Symmune Therapeutics General Information


Owner and operator of a biotech company intended to develop immune-based therapies. The company is focused on treating and preventing pulmonary infections and diseases by modulating the immune system, enabling clients to access their medical compound optimized for therapeutic activity and tolerability.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Other Healthcare Technology Systems
Primary Office
  • 212 West Main Street
  • Suite 304
  • Durham, NC 27701
  • United States
+1 (650) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Symmune Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Angel (individual) 08-Aug-2018 $125K 00000 Completed Startup
1. Debt - General 11-Sep-2015 00000 00000 Completed Startup
To view Symmune Therapeutics’s complete valuation and funding history, request access »